Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel

This study has been completed.
Information provided by (Responsible Party):
Fanny Bonhomme, University Hospital, Geneva Identifier:
First received: April 22, 2013
Last updated: August 18, 2014
Last verified: August 2014
The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.

Condition Intervention
Acquired Platelet Disorder
Other: Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Fanny Bonhomme, University Hospital, Geneva:

Primary Outcome Measures:
  • Platelet reactivity assessed by light transmittance aggregometry (LTA) after ex-vivo normal platelet addition [ Time Frame: within the first 6-24 hours after antiplatelet drug loading dose ]

Biospecimen Retention:   Samples Without DNA

Enrollment: 32
Study Start Date: September 2011
Study Completion Date: January 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Study patients
Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h)
Other: Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with acute coronary syndrome who received a loading dose of prasugrel within 6 and 24h.

Inclusion Criteria:

  • Acute coronary syndrome
  • Prasugrel loading dose 6-24h before inclusion

Exclusion Criteria:

  • Clopidogrel loading dose
  • GPIIbIIIa use within 10 days before inclusion
  • Known congenital thrombopathy and/or congenital coagulation defect
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01839968

University Hospital of Geneva
Geneva, GE, Switzerland, 1205
Sponsors and Collaborators
University Hospital, Geneva
  More Information

Responsible Party: Fanny Bonhomme, MD, University Hospital, Geneva Identifier: NCT01839968     History of Changes
Other Study ID Numbers: 11-117
Study First Received: April 22, 2013
Last Updated: August 18, 2014

Additional relevant MeSH terms:
Blood Platelet Disorders
Hematologic Diseases
Prasugrel Hydrochloride
Platelet Aggregation Inhibitors processed this record on May 25, 2017